Summary & Overview
HCPCS A9530: Iodine I-131 Sodium Iodide Solution, Therapeutic
HCPCS Level II code A9530 denotes therapeutic iodine I-131 sodium iodide solution billed per millicurie. This radiopharmaceutical code is nationally relevant for endocrinology, oncology, and nuclear medicine services, representing a unit-based supply component of radioactive iodine therapy used for hyperthyroidism and differentiated thyroid cancer. Accurate coding of A9530 affects billing for therapeutic doses, compliance with radiopharmaceutical handling rules, and coordination between providers and payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, common sites of service, and operational considerations tied to unit-based billing for therapeutic radiopharmaceuticals. The publication will also provide benchmarking guidance where available, summarize payer coverage patterns and policy considerations, and highlight documentation elements relevant to claims for unit-dosed I-131 therapy.
The content is intended to help coding managers, billing professionals, and clinical administrators understand how A9530 functions within therapeutic radioactive iodine workflows and payer interactions at a national level.
Billing Code Overview
HCPCS Level II code A9530 describes iodine I-131 sodium iodide solution, therapeutic, per millicurie. The service type is therapeutic radiopharmaceutical administration, primarily used for treatment of thyroid conditions such as hyperthyroidism and certain thyroid cancers. The typical site of service is outpatient specialty clinics, hospital outpatient departments, or nuclear medicine facilities where radioactive therapeutic agents are administered and monitored.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving A9530 is an adult with differentiated thyroid carcinoma or toxic multinodular goiter referred for therapeutic radioiodine (I-131) administration. The workflow begins with endocrinology or nuclear medicine evaluation confirming suitability based on diagnosis, pregnancy test for women of childbearing potential, informed consent, and pre-therapy laboratory testing (thyroid function tests, creatinine). Thyroid-stimulating hormone (TSH) is optimized (often via thyroid hormone withdrawal or recombinant human TSH) to maximize radioiodine uptake. A dosimetry or empiric therapeutic activity is determined; A9530 is billed per millicurie of sodium iodide I-131 solution dispensed for oral administration. On the day of therapy the patient receives the calculated millicurie dose in a controlled nuclear medicine outpatient or inpatient setting depending on activity and regulatory requirements. Post-therapy instructions include radiation safety precautions, follow-up thyroglobulin and imaging as indicated, and documentation of administered activity in millicuries and lot numbers for billing with A9530.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |